{
    "clinical_study": {
        "@rank": "6481", 
        "arm_group": [
            {
                "arm_group_label": "1) Add furosemide/no spironolactone", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "2) Add metolazone/no spironolactone", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "3) Add furosemide/spironolactone", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "4) Add metolazone/spironolactone", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the effectiveness and safety of diuretics add-on strategy in chronic heart\n      failure patients"
        }, 
        "brief_title": "A Prospective, Single-center, Open-label, Pilot Study to Compare the Effectiveness and Safety of Diuretics Add-On Strategy in Chronic Heart Failure Patients (DIOS 1)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Congestive Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. dyspnea at rest or minimal activity\n\n          2. tachypnea (respiratory rate > 20/min) or rales or pulmonary edema on chest X-ray\n\n          3. who need diuretics add over 40mg of daily furosemide dose\n\n        Exclusion Criteria:\n\n          1. Hospitalization for acute heart failure decompensation\n\n          2. cardiogenic shock (Systolic Blood Pressure < 80mmHg)\n\n          3. Need or plan for renal replacement therapy (dialysis, kidney transplant)\n\n          4. serum creatine level > 2.5mg/dl\n\n          5. serum potassium (K+) > 5.5mg/dl\n\n          6. daily spironolactone dose > 50mg\n\n          7. previous thiazide or metolazone user\n\n          8. Age > 75 years old or poor compliance patients 9. allergy, adverse drug reaction,\n             hypersensitivity to any kinds of diuretics 10. life expectancy < 6 months (e.g.\n             metastatic malignancy, liver cirrhosis) 11. pregnancy or women at age of childbearing\n             potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817803", 
            "org_study_id": "4-2013-0013"
        }, 
        "intervention": [
            {
                "arm_group_label": "1) Add furosemide/no spironolactone", 
                "description": "furosemide (doubling previous furosemide dose)", 
                "intervention_name": "furosemide/no spironolactone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2) Add metolazone/no spironolactone", 
                "description": "metolazone (add 2.5mg qod)", 
                "intervention_name": "metolazone/no spironolactone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3) Add furosemide/spironolactone", 
                "description": "furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)", 
                "intervention_name": "furosemid/spironolactone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4) Add metolazone/spironolactone", 
                "description": "metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)", 
                "intervention_name": "metolazone/spironolactone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Diuretics", 
                "Furosemide", 
                "Metolazone", 
                "Spironolactone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart failure", 
            "diuretics", 
            "kidney", 
            "glomerular filtration rate"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1) body weight change, symptoms & signs change, systemic impedance change 2)  serum & urine creatinine change, serum & urine electrolyte change, biomarkers change, clinical outcomes ( all-cause mortality, all-cause rehospitalization, start of renal replacement therapy)", 
            "measure": "efficacy and safety of diuretics add-on strategy", 
            "safety_issue": "No", 
            "time_frame": "D+0, D+7, D+30, D+90"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817803"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}